IPILIMUMABA in English translation

• of ipilimumab

Examples of using Ipilimumaba in Croatian and their translations into English

U bolesnika s teškim(3. stupanj) kožnim nuspojavama treba odgoditi primjenu planirane doze ipilimumaba.
For patients with a severe(Grade 3) skin adverse reaction, the scheduled dose of ipilimumab should be withheld.

produljenje PFS-a uz liječenje kombinacijom nivolumaba i ipilimumaba ustanovljeno je samo u bolesnika s niskom razinom tumorske ekspresije PD-L1.
an increase in PFS for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression.

Farmakokinetika ipilimumaba ispitivala se u 785 bolesnika s uznapredovalim melanomom koji su u uvodnoj terapiji primali doze u rasponu od 0, 3 do 10 mg/kg svaka 3 tjedna do ukupno 4 doze.
The pharmacokinetics of ipilimumab was studied in 785 patients with advanced melanoma who received induction doses ranging from 0.3 to 10 mg/kg administered once every 3 weeks for 4 doses.

bile su slične ili više od onih kod kliničke primjene ipilimumaba u dozi od 3 mg/kg.
levels either similar to or higher than those associated with the clinical dose of 3 mg/kg of ipilimumab.

Nakon ponovljenih doza ipilimumaba primijenjenih svaka 3 tjedna pronašlo se
Upon repeated dosing of ipilimumab administered every 3 weeks,

Klirens ipilimumaba povećavao se s povećanjem tjelesne težine
Ipilimumab clearance increased with increasing body weight

Primjena ipilimumaba mora se trajno obustaviti u bolesnika s vrlo teškim(4. stupanj)
Ipilimumab must be permanently discontinued in patients with a very severe(Grade 4)

U bolesnika s teškim(3. ili 4. stupanj) proljevom ili kolitisom(vidjeti dio 4.2) primjena ipilimumaba mora se trajno prekinuti i odmah započeti s intravenskom terapijom visokim dozama sistemskih kortikosteroida.
Ipilimumab must be permanently discontinued in patients with severe(Grade 3 or 4) diarrhoea or colitis(see section 4.2),

povećavao se s porastom minimalnih koncentracija ipilimumaba u plazmi u stanju dinamičke ravnoteže Cminss.
systemic anti-cancer therapy and increased with higher ipilimumab Cminss plasma concentrations.

uz liječenje kombinacijom nivolumaba i ipilimumaba ustanovljeno je samo u bolesnika s niskom razinom tumorske ekspresije PD-L1 vidjeti dijelove 4.4 i 5.1.
for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression see sections 4.4 and 5.1.

Sigurnosni profil ipilimumaba u dozi od 3 mg/ kg u objedinjenoj populaciji bolesnika iz kliničkih ispitivanja faze II
The safety profile of ipilimumab 3 mg/kg in chemotherapy-naive patients pooled across Phase 2 and 3 clinical trials(N= 75;

Ako imate bilo kakvih pitanja o ipilimumabu, obratite se svom liječniku.
If you have any questions about ipilimumab, please ask your doctor.

Kada se OPDIVO primjenjuje u kombinaciji s ipilimumabom, preporučena doza lijeka OPDIVO je 1 mg nivolumaba po kilogramu tjelesne težine kod prve 4 doze faza kombinirane terapije.
When OPDIVO is given in combination with ipilimumab the recommended dose of OPDIVO is 1 mg of nivolumab per kilogram of your body weight for the first 4 doses combination phase.

U ovim istraživanjima, INCB024360 prašak u kombinaciji s CTLA-4 inhibitorom ipilimumabom ili PD-1 inhibitorom KEYTRUDA poboljšao je stopu odgovora u usporedbi s istraživanjima samih inhibitora imunog kontrolnog toka.
In these studies, INCB024360 powder combined with the CTLA-4 inhibitor ipilimumab or the PD-1 inhibitor KEYTRUDA improved response rates compared with studies of the immune checkpoint inhibitors alone.

Ukupno je 945 bolesnika bilo randomizirano u skupine koje su primale nivolumab u kombinaciji s ipilimumabom(n 314), nivolumab u monoterapiji(n 316)
A total of 945 patients were randomised to receive nivolumab in combination with ipilimumab(n 314), nivolumab monotherapy(n 316),

U kliničkim ispitivanjima nivolumaba u kombinaciji s ipilimumabom, u manje od 1% bolesnika prijavljene su sljedeće dodatne klinički značajne imunološki uzrokovane nuspojave:
Across clinical trials of nivolumab in combination with ipilimumab, the following additional clinically significant, immune-related adverse reactions were reported in less than 1% of patients:

Nuspojave zabilježene u bolesnika s uznapredovalim melanomom koji su bili liječeni lijekom ipilimumabom u dozi od 3 mg/kg u kliničkim ispitivanjima(n= 767)
Adverse reactions reported in patients with advanced melanoma who were treated with ipilimumab 3 mg/kg in clinical trials(n= 767)

Liječenje nivolumabom ili nivolumabom u kombinaciji s ipilimumabom mora se trajno prekinuti u slučaju teške(3. stupanj)
Nivolumab or nivolumab in combination with ipilimumab must be permanently discontinued for severe(Grade 3)

Liječenje nivolumabom ili nivolumabom u kombinaciji s ipilimumabom ne smije se nastaviti dok bolesnik prima imunosupresivne doze kortikosteroida ili drugog imunosupresivnog lijeka.
Nivolumab or nivolumab in combination with ipilimumab should not be resumed while the patient is receiving immunosuppressive doses of corticosteroids or other immunosuppressive therapy.

onda moramo početi razmišljati o tome što biste kombinirali s ipilimumabom.
then we have to start thinking about what you would combine with ipilimumab.